Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate

Journal of Pharmaceutical Sciences

Volumn 99, Issue 4, 2010, Pages 1639-1653

  Jantratid, E ^a   Strauch, S ^a   Becker, C ^a,b   Dressman, J B ^a   Amidon, G L ^c   Junginger, H E ^d   Kopp, S ^e   Midha, K K ^f   Shah, V P ^g   Stavchansky, S ^h   Barends, D M ⁱ  

^a GOETHE UNIVERSITY   (Germany)

^b BAYER AG   (Germany)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NARESUAN UNIVERSITY   (Thailand)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

^g International Pharmaceutical Federation FIP   (Netherlands)

^h UNIVERSITY OF TEXAS AT AUSTIN   (United States)

ⁱ NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Absorption; Biopharmaceutics classification system (BCS); Doxycycline hyclate; Permeability; Regulatory science; Solubility

Indexed keywords

ALGINIC ACID; ALUMINUM HYDROXIDE; CALCIUM PHOSPHATE DIBASIC; CELLULOSE; CROSCARMELLOSE SODIUM; CROSPOVIDONE; DIMETICONE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; ETHYL CELLULOSE; EXCIPIENT; GELATIN; HYDROGENATED CASTOR OIL; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MACROGOL; MAGNESIUM STEARATE; MAGNESIUM TRISILICATE; METHYLCELLULOSE; MINOCYCLINE; MONOACYLGLYCEROL; POLYSORBATE 80; POLYVINYL ALCOHOL; POVIDONE; PROPOLIS; PROPYLENE GLYCOL; QUININE; SHELLAC; SILICON DIOXIDE;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EXCRETION; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; ENAMEL HYPOPLASIA; ESOPHAGUS ULCER; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GONORRHEA; HUMAN; KIDNEY FAILURE; KIDNEY INJURY; LIVER INJURY; MALARIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; NOTE; PANCREATITIS; PARTITION COEFFICIENT; PHOTOSENSITIVITY; PHYSICAL CHEMISTRY; PKA; PORPHYRIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; STEREOISOMERISM; STOMACH LAVAGE; SYPHILIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH DISCOLORATION; URINARY TRACT INFECTION; VOMITING;

EID: 77949783458     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21954     Document Type: Article

References (94)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93: 1945-1956.
2. World Health Organization (WHO). 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. Available from: http://whqlibdoc.who.int/trs/WHO- TRS-937-eng.pdf. Accessed Date: May 20, 2009.
3. U.S., Department of Health and Human Services, Food and Drug Administration, Center for Evaluation and Research (CDER). 2000. Guidances for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Available from: http://www.fda.gov/CDER/GUIDANCE/3618fnl. pdf. Accessed Date: May 20, 2009.
4. European Medicines Evaluation Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP). 2001. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. Available from: http://www.emea.eu.int/pdfs/ human/ewp/140198en.pdf. Accessed Date: May 20, 2009.
5. Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). J Pharm Sci 95:4-14.
6. Granero GE, Longhi MR, Becker C, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Acetazolamide. J Pharm Sci 97:3691-3699.
7. Arnal J, Gonzalez-Alvarez I, Bermejo M, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir. J Pharm Sci 97:5061-5073.
8. Manzo RH, Olivera ME, Amidon GL, Shah VP, Dressman JB, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Amitriptyline hydrochloride. J Pharm Sci 95:966-973.
9. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. J Pharm Sci 94:1389-1395.
10. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sci 95:974-984.
11. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium. J Pharm Sci 98:1206-1219.
12. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride. J Pharm Sci 97:1350-1360.
13. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 94: 2121-2131.
14. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid. J Pharm Sci 96:522-531.
15. Stosik AG, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Metoclopramide hydrochloride. J Pharm Sci 97:3700-3708.
16. Vogt M, Derendorf H, Krämer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone. J Pharm Sci 96:27-37.
17. Vogt M, Derendorf H, Krämer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisone. J Pharm Sci 96:1480-1489.
18. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide. J Pharm Sci 97:3709-3720.
19. Grube S, Langguth P, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Quinidine sulfate. J Pharm Sci 98:2238-2251.
20. Kortejärvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride. J Pharm Sci 94:1617-1625.
21. Becker C, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin. J Pharm Sci 98:2252-2267.
22. International Pharmaceutical Federation (FIP). 2009. Biopharmaceutics Classification System (BCS). Available from: http://www.fip.org/bcs. Accessed Date: May 20.
23. World Health Organization (WHO). 2009. Guidance on the use of International Nonproprietary Names (INNs) for pharmaceutical substances. Available from: http://whqlibdoc.who.int/hq/1997/WHO-PHARM-S-NOM-1570.pdf. Accessed Date: May 20, 2009.
24. World Health Organization (WHO). 2006. International Nonproprietary Names Modified. Available from: http://www.who.int/medicines/services/inn/ INNMreview%20paperWkDoc167-Feb06-3-.pdf. Accessed Date: May 20, 2009.
25. World Health Organization (WHO)., 2007. Doxycycline hyclate: Final text to replace published monograph in The International Pharmacopoeia. Available from: http://www.who.int/entity/medicines/publications/pharmacopoeia/QAS06- 185FINAL-DoxyHyclateRevMono-Nov07.pdf. Accessed Date: May 20, 2009.
26. Martindale. 2006. The Complete Drug Reference, Electronic Version. Available from: http://www.medicinescomplete.com/mc/martindale/2006/. Accessed Date: May 20, 2009.
27. United States National Library of Medicine. 2007. Available from: http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Accessed Date: May 20, 2009.
28. The Japanese Pharmacopoeia 15 (JP XV). 2006. Available from: http://jpdb.nihs.go.jp/jp15e/JP15.pdf. Accessed Date: May 20, 2009.
29. Sigma-Aldrich. 2007. D9891-Product information sheet-doxycycline hyclate. Available from: http://www.sigmaaldrich.com/catalog/DataSheetPage.do?brandKey= SIGMA&symbol=D9891. Accessed Date: May 20, 2009.
30. Brunton L, Lazo J, Parker K. 2006. Goodman & Gilman's. The Pharmacological Basis of Therapeutics, 11th edition. New York: McGraw-Hill Medical Publishing Division.
31. World Health Organization (WHO). 2007. WHO Model Lists of Essential Medicines, 15th ed. Available from: http://www.who.int/entity/medicines/ publications/08-ENGLISH-indexFINAL-EML15.pdf. Accessed Date: May 20, 2009.
32. U.S., Food and Drug Administration, Department of Health and Human Services, Center for Devices and Radiological Health. 2008. Title 21 - Food and Drugs, Chapter I - Subchapter D - Drugs for Human Use - Part 320 - Bioavailability and Bioequivalence Requirements. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart= 320. Accessed Date: March 18, 2009.
33. The Merck Index. 2005. 13th edition. Rahway, New Jersey: Merck Research Laboratories.
34. Valean S, Petrescu M, Catinean A, Chira R, Mircea PA. 2005. Pill esophagitis. Rom J Gastroenterol 14:159-163.
35. Kadayifci A, Gulsen MT, Koruk M, Savas MC. 2004. Doxycycline-induced pill esophagitis. Dis Esophagus 17:168-171.
36. Gröchenig HP, Tilg H, Vogetseder W. 2006. Clinical challenges and images in GI. Pill esophagitis. Gastroenterology 131:996.
37. Malmborg AS. 1984. Bioavailability of doxycycline monohydrate. A comparison with equivalent doses of doxycycline hydrochloride. Chemotherapy 30:76-780.
38. Tanaka N, Kawada A, Ohnishi Y, Hiruma M, Tajima S, Akiyama M, Ishibashi A. 1997. Photosensitivity due to doxycycline hydrochloride with an unusual flare. Contact Dermatitis 37:93-94.
39. Yong CK, Prendiville J, Peacock DL, Wong LT, Davidson AG. 2000. An unusual presentation of doxycycline-induced photosensitivity. Pediatrics 106:E13.
40. Saivin S, Houin G. 1988. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15:355-366.
41. Fung WK, Tam SC, Ho KM, Lam P, Lo KK. 2001. Porphyria cutanea tarda and melioidosis. Hong Kong Med J 7:197-200.
42. Rote-Liste® Service GmbH. 2007. Arzneimittelsverzeichnis für Deutschland (einschlieβlich EU-Zulassungen und bestimmter Medizinprodukte) (German). Available from: http://www.roteliste.de/Online. Accessed Date: March 18, 2009.
43. The United States Pharmacopeia The National Formulary (USP 32/NF 27), edition. Rockville, MD: The United States Pharmacopeial Convention, Inc.
44. The European Pharmacopoeia (Ph.Eur.). 2005. 5th ed., Strasbourg, France: European Directorate for the Quality of Medicines, Council of Europe.
45. The British Pharmacopoeia (B.P.). 1993. ed., London, the United Kingdom: The British Pharmacopoeia Secretariat.
46. The World Health Organization (WHO). 2008. The International Pharmacopoeia 4th ed. Available from: http://apps.who.int/phint/en/p/about/. Accessed Date: May 20, 2009.
47. Sigma-Aldrich. 2007. Product information sheet - D9891 Doxycycline hyclate. Available from: http://www.sigmaaldrich.com/catalog/ProductDetail.do? lang=de&N4=D9891|SIGMA&N5=SEARCH-CONCAT-PNO|BRAND-KEY&F=SPEC. Accessed Date: May 20, 2009.
48. World Health Organization (WHO). 2008. The International Pharmacopoeia 4th ed. Available from: http://www.who.int/phint/en/p/about/. Accessed Date: May 20, 2009.
49. Stippler E. 2004. Biorelevant dissolution test methods to assess bioequivalence of drug products. Doctoral Thesis, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
50. Strauch S, Jantratid E, Dressman JB. 2009. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products. J Pharm Pharmacol 61:331-337.
51. Choi KJ, Kim SG, Kim CW, Kim SH. 2007. Determination of antibiotic compounds in water by on-line SPE-LC/MSD. Chemosphere 66:977-984.
52. Durckheimer W. 1975. Tetracyclines: Chemistry, biochemistry, and structure-activity relations. Angew Chem Int Ed Engl 14:721-734.
53. Grahnen A, Olsson B, Johansson G, Eckernas SA. 1994. Doxycycline carrageenate - An improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. Eur J Clin Pharmacol 46:143-146.
54. The European Pharmacopoeia (Ph.Eur.). 2005. Pharm. Eur. Kommentar (German), 5th Ed. Strasbourg, France: European Directorate for the Quality of Medicines, Council of Europe.
55. Danish Medicines Agency. Available from: http://www.dkma.dk/1024/ visUKLSForside.asp?artikelID=728. Accessed Date: March 18, 2009.
56. Lääkelaitos Läkemedelsverket, National Agency for Medicines. Available from: http://www.nam.fi/. Accessed Date: March 18, 2009.
57. VIDAL L'information de re'fe'rence sur les produits de sante' (French). Available from: http://www.vidal.fr/. Accessed Date: March 18, 2009.
58. Medicines Evaluation Board. Available from: http://www.cbg-meb.nl/cbg/en/ default.htm. Accessed Date: March 18, 2009.
59. Norwegian Medicines Agency. Available from: www.legemiddelverket.no. Accessed Date: March 18, 2009.
60. Agencia espanola de midecamentos y productos sanitarios. Available from: http://www.agemed.es/. Accessed Date: March 18, 2009.
61. Medical Products Agency. Available from: http://www.lakemedelsverket.se/. Accessed Date: March 18, 2009.
62. Datapharm Communications L. Available from: http://www.medicines.org.uk/. Accessed Date: March 18, 2009.
63. DailyMed Current Medication Information. Available from: http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed Date: March 18, 2009.
64. Jack DB. 1992. Handbook of clinical pharmacokinetic data, 1st edition. Basingstoke, the United Kingdom: Macmillan Publishers Ltd.
65. Saux MC, Mosser J, Pontagnier H, Leng B. 1981. Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). Eur J Drug Metab Pharmacokinet 6:3-10.
66. Fabre J, Pitton JS, Kunz JP. 1966. Distribution and excretion of doxycycline in man. Chemotherapy 11:73-85.
67. Welling PG, Koch PA, Lau CC, Craig WA. 1977. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother 11:462-469.
68. Kshirsagar NA, Ankalesaria PS. 1987. Effect of food on doxycycline absorption. J Postgrad Med 33:117-119.
69. Pfizer Ltd. Summary of product characteristics: Vibramycin 50 capsules. Available from: http://emc.medicines.org.uk/medicine/1475. Accessed Date: March 5, 2009.
70. Saitoh R, Sugano K, Takata N, Tachibana T, Higashida A, Nabuchi Y, Aso Y. 2004. Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm Res 21:749-755.
71. Böcker R, Muhlberg W, Platt D, Estler CJ. 1986. Serum level, half-life and apparent volume of distribution of doxycycline in geriatric patients. Eur J Clin Pharmacol 30:105-108.
72. Böcker R, Estler CJ, Weber A. 1982. Metabolism of doxycycline. Lancet 2:1155.
73. Garraffo A, Dellamonica P, Fournier JP, Lapalus P, Bernard E. 1988. The effect of rifampicin on the pharmacokinetics of doxycycline. Infection 16:297-2298.
74. Gschwend MH, Martin W, Erenmemisoglu A, Scherm M, Dilger C, Tamur U, Kanzik I, Hincal AA. 2007. Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. Arzneimittelforschung 57:347-351.
75. Kees F, Dehner R, Dittrich W, Raasch W, Grobecker H. 1990. Untersuchungen zur Bioverfugbarkeit von Doxycyclin. Arzneimittelforschung 40:1039-1043.
76. Fenner R. 2000. Arzneistoffe, 3rd edition. Stuttgart: Deutscher Apotheker Verlag. pp 61-62.
77. Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, Tillement JP. 1983. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol 16:245-252.
78. Antal EJ, Jaffe JM, Poust RI, Colaizzi JL. 1975. Bioequivalency of doxycycline products. J Pharm Sci 64:2015-2018.
79. Hampel B, Lode H, Fenner H, Gikalov I. 1980. Doxycyclin-Pellets: eine wirkstoffgerechte Darreichungsform mit gesicherter Bioäquivalenz. Arzneimittelforschung 30:1938-1943.
80. Campistron G, Coulais Y, Caillard C, Mosser J, Pontagnier H, Houin G. 1986. Pharmacokinetics and bioavailability of doxycycline in humans. Arzneimittelforschung 36:1705-1707.
81. Linberg LF, Tsirlina LA, Mashilov VP, Lisukova TE, Kashin AM, Alikeeva GK, Kuznetsov VF, Milova OG. 1987. Pharmacokinetics of doxycycline. Pharm Chem J 23:16-19.
82. Lode H, Deppermann N, Schmidt U. 1989. Bioäquivalenz einer optimierten Doxycyclin-Zubereitung. Arzneimittelforschung 39:1162-1165.
83. Saano V, Paronen P, Peura P. 1990. Bioavailability of doxycycline from dissolved doxycycline hydrochloride tablets - Comparison to solid form hydrochloride tablets and dissolved monohydrate tablets. Int J Clin Pharmacol Ther Toxicol 28:471-474.
84. Balogh A, Rechenbach C, Brix R, Mundhenke J, Tjuljumbow R, Hoffmann A. 1991. Untersuchungen zur Bioäquivalenz von Doxycyclin bei zwei Praparaten in Kapselzubereitung. Arzneimittelforschung 41:1289-1293.
85. Saket M, Qaisi A, MAbdel-Razzak M, Amro B, Tutunji M, Gharaibeh M, Zmeili S, Muti H. 1993. A bioequivalence study of two brands of doxycycline capsules. Curr Ther Res 54:15-22.
86. Kitzes-Cohen R, Farin D, Laor A, Piva G, Hazan K, Wasserman A, Gozlan I. 1998. Bioequivalence study of two formulations of doxycycline. Curr Ther Res 59:315-323.
87. Alsarra IA, Al-Said MS, Al-Khamis KI, Niazy EM, El-Sayed YM, Al-Rashood KA, Al-Yamani MJ, Al-Balla SA. 2004. Comparative bioavailability study of doxycycline hyclate (equivalent to 100mg doxycycline) capsules (doxycin vs. vibramycin) for bioequivalence evaluation in healthy adult volunteers. Int J Clin Pharmacol Ther 42:373-377.
88. Blume H, Siewert M, Stenzhorn G, Kübel-Thiel K. 1987. ZL-Monographie zur Prüfung der Bioverfügbarkeit/Bioäquivalenz (Entwurf). Pharmazeutische Zeitung 132:2476-2480.
89. Gleiter CH, Klotz U, Kuhlmann J, Blume H, Stanislaus F, Harder S, Paulus H, Poethko-Muller C, Holz-Slomczyk M. 1998. When are bioavailability studies required? A German proposal. J Clin Pharmacol 38:904-911.
90. College ter Beoordeling van Geneesmiddelen (CBG). 2009. Bio-equivalentieonderzoek lijst vrijstellingen. Available from: http://www.cbg-meb.nl/CBG/nl/humane-geneesmiddelen/geneesmiddelen/ allergie-informatie/default.htm#Bio-equivalentieonderzoek. Accessed Date: March 18. 2009.
91. Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. 1989. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 33:1901-1907.
92. Bogardus JB, Blackwood RK, Jr. 1979. Dissolution rates of doxycycline free base and hydrochloride salts. J Pharm Sci 68:1183-1184.
93. ICH. 2005. Quality risk management. ICH Harmonised Tripartite Guideline Q9. Available from: http://www.ich.org/LOB/media/MEDIA1957.pdf. Accessed Date: August 20, 2009.
94. Pan American Health Organization, Regional Office of the World Health Organization, Pan American Network for Drug Regulatory Harmonization. 2005. Science based criteria for bioequivalence testing (in vitro and in vivo), bio-waivers and strategy for implementation. Available from: www.amro.who.int/english/ad/ths/ev/be-doct-draft-eng.pdf. Accessed Date: May 20, 2009.